Persistence of Adverse Drug Reaction-Related Hospitalization Risk Following Discharge.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
04 05 2022
Historique:
received: 31 03 2022
revised: 25 04 2022
accepted: 29 04 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 18 5 2022
Statut: epublish

Résumé

This retrospective cohort study analyzed the administrative hospital records of 91,500 patients with the aim of assessing adverse drug reaction (ADR)-related hospital admission risk after discharge from ADR and non-ADR-related admission. Patients aged ≥18 years with an acute admission to public hospitals in Tasmania, Australia between 2011 and 2015 were followed until May 2017. The index admissions (n = 91,550) were stratified based on whether they were ADR-related (n = 2843, 3.1%) or non-ADR-related (n = 88,707, 96.9%). Survival analysis assessed the post-index ADR-related admission risk using (1) the full dataset, and (2) a matched subset of patients using a propensity score analysis. Logistic regression was used to identify the risk factors for ADR-related admissions within 90 days of post-index discharge. The patients with an ADR-related index admission were almost five times more likely to experience another ADR-related admission within 90 days (p < 0.001). An increased risk persisted for at least 5 years (p < 0.001), which was substantially longer than previously reported. From the matched subset of patients, the risk of ADR-related admission within 90 and 365 days more than doubled in the patients with an ADR-related index admission (p < 0.0001). These admissions were often attributed to the same drug class as the patients’ index ADR-related admission. Cancer was a major risk factor for ADR-related re-hospitalization within 90 days; other factors included heart failure and increasing age.

Identifiants

pubmed: 35564982
pii: ijerph19095585
doi: 10.3390/ijerph19095585
pmc: PMC9101512
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
Br J Clin Pharmacol. 2010 Nov;70(5):749-55
pubmed: 21039769
Drug Saf. 2017 Jul;40(7):597-606
pubmed: 28382494
Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1281-1285
pubmed: 30264866
PLoS One. 2012;7(3):e33236
pubmed: 22438900
Drugs Aging. 2012 Mar 1;29(3):225-232
pubmed: 22372725
Drugs Aging. 2017 Oct;34(10):777-783
pubmed: 28952130
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Drug Saf. 2020 Jun;43(6):517-537
pubmed: 32125666
Eur J Clin Pharmacol. 2008 Jul;64(7):715-22
pubmed: 18385990
Br J Clin Pharmacol. 2014 Aug;78(2):202-17
pubmed: 24283967
BMJ. 2009 Jan 07;338:a2752
pubmed: 19129307
Public Health Res Pract. 2017 Apr 27;27(2):
pubmed: 28474053
Age Ageing. 2019 Dec 1;49(1):7-11
pubmed: 31665207
Drug Metab Rev. 2009;41(2):67-76
pubmed: 19514965
BMC Health Serv Res. 2013 Nov 12;13:473
pubmed: 24219303
Eur J Clin Pharmacol. 2017 Jun;73(6):759-770
pubmed: 28251277
Intern Med J. 2019 Jan;49(1):84-93
pubmed: 30281186
N Engl J Med. 2009 Oct 15;361(16):1521-3
pubmed: 19797277
Intern Med J. 2006 Apr;36(4):221-5
pubmed: 16640738
World Health Organ Tech Rep Ser. 1972;498:1-25
pubmed: 4625548
Eur J Clin Pharmacol. 2016 May;72(5):631-9
pubmed: 26884320

Auteurs

Olive Schmid (O)

School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia.

Bonnie Bereznicki (B)

Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia.

Gregory Mark Peterson (GM)

School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia.

Jim Stankovich (J)

School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia.

Luke Bereznicki (L)

School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH